

- Aspiration  
 cough in, 244  
 in dysphagia, 257  
 dyspnea in, 47e-4  
 with enteral feeding, 98e-8–9  
 in opioid use disorders, 468e-2  
 pneumonia and, 804  
 pneumonitis and, 1098. *See also* Pneumonitis of vomitus, 259
- Aspirin, **746**  
 action of, 746, 746f  
 for acute pericarditis, 1573  
 adverse effects of  
   anaphylaxis, 44  
   asthma exacerbation, 1680  
   bleeding, 404, 746  
   cutaneous, 377, 381  
   eosinophilia, 422  
   gastric irritation/bleeding, 90, 746, 1590  
   gout, 2218t  
   immunologic factors in, 377  
   nephropathy, 1861  
   Reye's syndrome, 1184, 1185, 1213  
   uricosuria, 431e-5  
 allergy to, 746  
 for antiphospholipid syndrome, 2136  
 for atherosclerosis prevention, 291e-9  
 for Behçet's syndrome, 2194  
 for breast cancer prevention, 524  
 for cardiac catheterization pretreatment, 1461  
 chronic use in cardiac disease, 2566t  
 with clopidogrel, 747  
 for colorectal cancer prevention, 477, 539  
 for coronary heart disease prevention, 29t, 291e-9  
 dosage of, 746  
 for erythromelalgia, 1650  
 for fever, 126  
 genetic variation in response to, 277, 277t, 742, 743t  
 for giant cell arteritis, 2189  
 indications for, 746  
 for ischemic heart disease, 1590  
 for ischemic stroke, 2563  
 for Kawasaki disease, 2193  
 low-dose, 34, 241, 277  
 management of  
   before endoscopic procedures, 1889t  
   before lumbar puncture, 443e-1  
   perioperative, 54  
 for medication-overuse headache, 109  
 metabolism of, 34  
 for migraine, 2592t  
 for myocardial infarction  
   NSTEMI-ACS, 1596, 1598t  
   as secondary prevention, 1610  
   STEMI, 1603, 1606, 1610  
 for niacin-associated flushing, 96e-4  
 for pain, 90–91, 91t  
 in PCI, 296e-1, 296e-2, 1591  
 for peripheral artery disease, 1645  
 for preeclampsia prevention in high-risk women, 45  
 for rheumatic fever, 2152–2153  
 for stroke/TIA prevention, 291e-9, 2569–2570  
 for subacute thyroiditis, 2299  
 for tension-type headache, 2594  
 in women, 6e-3
- Aspirin resistance, 1596  
 Aspirin-sensitive asthma, 1680  
 Asplenia, 375e-1, 413, 788f, 2104–2105  
 Assassin bug bite, 2750  
 Assist control ventilation (ACMV), 1741, 1742t.  
   *See also* Mechanical ventilation
- Assisted living, 83, 83t  
 Assisted reproductive technologies, 2360, 2389  
 Association cortex, 176, 176f  
 Association study, 442, 442t  
 Associative prosopagnosia, 182  
 AST. *See* Aspartate aminotransferase (AST)  
 Asstasia-abasia, 164
- Asteatotic eczema, 342f, 346  
 Astereognosis, 160  
 Asterixis, 1773  
 Asthenia, 462e-1, 1212  
 Asthma, **1669**  
 acute severe, 1679  
 air pollution and, 1670  
 allergies and, 1669–1670, 1671  
 aspirin-sensitive, 1680  
 atopy and, 1669–1670  
 brittle, 1680  
 bronchopulmonary aspergillosis in, 1681  
 cardiac, 1504  
 chronic, 1678–1679  
 clinical features of, 1675  
 corticosteroid-resistant, 1680  
 cough in, 244  
 cough-variant, 244  
 diagnosis of, 1675–1676, 1675f  
 dietary factors in, 1670  
 differential diagnosis of, 1676  
 drug-induced, 1671  
 dyspnea in, 47e-1t, 47e-2, 47e-2t, 47e-3  
 in elderly, 1680  
 environmental factors in, 1670–1671  
 exercise-induced, 1671  
 with fungal sensitization, 1348  
 genetic considerations in, 1670  
 high-altitude travel and, 476e-5  
 hygiene hypothesis of, 1670  
 infections and, 1670, 1671  
 inflammatory mediators in, 372e-29t  
 intrinsic, 1671  
 noncompliance with medication for, 1679–1680  
 occupational, 1670  
 pathophysiology of, 306e-3, **1671**, 1673f  
   airway hyperresponsiveness, 1675  
   airway inflammation, 1672–1673, 1672f  
   airway remodeling, 1675  
   inflammatory effects, 1674–1675  
   inflammatory mediators, 1673–1674, 1673f  
   pathology, 1671–1672, 1672f  
   physiology, 1675  
 in pregnancy, 1680  
 prevalence of, 1669  
 pulmonary function values in, 306e-5, 306e-5f  
 refractory, 1679–1680  
 respiratory acidosis in, 322  
 risk factors for, 1670t, 1671  
 smoking and, 1680  
 in surgical patient, 1680–1681  
 treatment of, **1676**  
   in acute severe disease, 1679  
   alternative therapies, 1678  
   anticholinergics, 1676–1677  
   antileukotrienes, 1678  
    $\beta_2$ -agonists, 1676  
   bronchodilators, 1676  
   in chronic disease, 1678–1679  
   cromones, 1678  
   future directions in, 1678  
   goals of, 1676t, 1678–1679, 1679t  
   immunotherapy, 1678  
   inhaled corticosteroids, 1677, 1678f  
   omalizumab, 1678  
   patient education, 1679  
   in refractory disease, 1680  
   stepwise approach to, 1679, 1679f  
   steroid-sparing therapies, 1678  
   systemic corticosteroids, 1677–1678  
   theophylline, 1677, 1677t  
   triggers of, 1670t, 1671
- Astigmatism, 195  
 Astrakhan spotted fever, 1157  
 Astrocytomas  
   glioblastoma, 599–600, 600f  
   high-grade, 600  
   intramedullary, 2654, 2654f  
   low-grade, 599–600  
   pilocytic, 441e-39f  
 Astroviruses, 1286f, 1286t, 1289
- Asunaprevir, 2049  
 ASXL1 gene mutations, 135e-6, 680, 680t  
 Asymptomatic bacteriuria, 861, 863, 866, 868  
 Asystole, 1769f. *See also* Cardiac arrest  
 AT. *See* Atrial tachycardia (AT)
- Ataxia, **2626**  
 approach to the patient, 2626–2627  
 autosomal dominant  
   dentatorubropallidolysian atrophy, 440t, 451e-2t, 2629  
   episodic ataxia, 444e-2t, 451e-3t, 2629  
   spinocerebellar ataxia. *See* Spinocerebellar ataxia (SCA)  
 autosomal recessive. *See* Ataxia telangiectasia (AT); Friedreich's ataxia  
 cerebellar. *See* Cerebellar ataxia  
 channelopathies in, 444e-2t  
 chemotherapy-induced, 607t  
 clinical features of, 33e-1v, 2626  
 diseases associated with, 2626–2627  
 focal, 2627  
 global considerations in, 2631  
 mitochondrial, 2630  
 in MS, 2663, 2672  
 optic, 181  
 pathophysiology of, 87e-2, 87e-3t  
 postinfectious, 2626  
 sensory, 158, 163, 164t  
 symmetric, 2626–2627  
 toxin-induced, 2626  
 treatment of, 2630, 2672  
 video library, 33e-1v  
 with vitamin E deficiency, 2630
- Ataxia telangiectasia (AT)  
 clinical features of, 451e-3t, 2109, 2630  
 diagnosis of, 2109  
 genetic considerations in  
   ATM gene mutations, 101e-6t, 434, 451e-3t, 2630  
   DNA repair defects, 375e-1, 434, 2630  
   incidence of, 2109  
   lymphoid malignancies in, 375e-1, 2109, 2630  
   pancreatic cancer risk in, 554  
   pathology of, 2630  
   treatment of, 2630
- Ataxia-telangiectasia mutated (ATM), 102e-2  
 Ataxia with oculomotor apraxia (AOA1), 451e-3t  
 Ataxia with oculomotor apraxia (AOA2), 451e-3t  
 Ataxin-1, 2628  
 Ataxins, 2627  
 Atazanavir  
   adverse effects of, 1258, 1259, 1275t, 1278, 1280  
   drug interactions of, 1278, 1280, 1921  
   for HIV infection, 1275t, 1278  
   molecular structure of, 1276f  
   resistance to, 1278, 1280f
- Atelectasis, 1732  
 Atenolol  
   for adrenergic symptoms in Graves' disease, 2296  
   for arrhythmias, 1480t  
   dosage of, 1480t  
   for hypertension, 1624t  
   for ischemic heart disease, 1589t  
   overdosage/poisoning with, 473e-9t
- ATF1 gene mutations, 101e-3t  
 ATG. *See* Antithymocyte globulin (ATG)  
 Atherectomy, 296e-2  
 Athroembolism, 1629, 1646, 1647f, 1806t  
 Atherosclerosis, **291e-1**  
 aging and, 94e-4  
 aortic, 1638, 1642  
 cardiovascular risk reduction in, 291e-6t, 291e-7f, 291e-8f, 291e-8t  
 carotid. *See* Carotid stenosis  
 consequences of, 291e-4  
 coronary. *See* Coronary artery disease (CAD)  
 endothelium in, 265e-2  
 in familial hypercholesterolemia, 2441–2442  
 hypertension and, 1614  
 inflammatory mediators in, 372e-29t  
 intracranial, 2572